NOVALIQ’S NOVATEARS® TREATMENT FOR EVAPORATIVE DRY EYE DISEASE IS NOW AVAILABLE ACROSS AUSTRALIA AND NEW ZEALAND

Heidelberg, Germany – June 28, 2018 – Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced that NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), is now also available in Australia. Dry eye is…

Details
Novaliq at Ophthalmology Technology Summit 2018

Novaliq at Ophthalmology Technology Summit 2018

We are delighted that Novaliq was selected as one of only four companies to present in OCTANe’s LaunchPad session during the Ophthalmology Technology Summit taking place in Newport Beach, CA on June 29, 2018. Novaliq Inc‘s president, Bernhard Günther, will present between 3:15-4:15 p.m. https://www.ots2018.com/agenda/